LivaNova PLC — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
LivaNova reported Q3 2026 revenue of $393.1M (10.0% constant-currency growth), with Cardiopulmonary up 10.9% and Neuromodulation up 11.2%. The company raised full-year 2026 revenue guidance to 9-10% (from 8-9%) and adjusted diluted EPS guidance to $4.40-$4.50 (from $4.30-$4.40, +$0.10 midpoint), assuming ~56M shares. Q3 adjusted diluted EPS was $1.23 vs. $1.11 prior year. Key milestone: operational launch of dedicated oxygenator manufacturing line. AMA approved new CPT codes for proximal hypoglossal nerve stimulation (effective Jan 1, 2028). CORE-VNS study published 36-month results showing 76% median seizure reduction.
Why this rating
Modest revenue beat and guidance raise signal solid execution; manufacturing capacity expansion meaningful. At ~$2.5B market cap, $393M Q3 revenue is ~6% annualized, and $0.10 EPS raise midpoint is ~2.3% of prior $4.35 guidance. Real but not transformational.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.